scholarly journals 191P Real-world data (RWD) on the long-term outcomes of the addition of carboplatin to standard neoadjuvant chemotherapy in triple-negative stage I-III breast cancer

2021 ◽  
Vol 32 ◽  
pp. S441
Author(s):  
A. Hanif ◽  
G. Mujtaba ◽  
S.Y. Goksu ◽  
H.S. Sheikh
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Real World ◽  
Triple Negative ◽  
Stage I ◽  
Long Term Outcomes ◽  
Real World Data ◽  
World Data

scholarly journals Prognostic factors for early relapse in non-metastatic triple negative breast cancer — real world data

2021 ◽  
Author(s):  
Rita Félix Soares ◽  
Ana Rita Garcia ◽  
Ana Raquel Monteiro ◽  
Filipa Macedo ◽  
Tatiana Cunha Pereira ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Triple Negative Breast Cancer ◽  
Real World ◽  
Triple Negative ◽  
Real World Data ◽  
Early Relapse ◽  
World Data

scholarly journals Use of real-world data to study health services utilisation and comorbidities in long-term breast cancer survivors (the SURBCAN study): study protocol for a longitudinal population-based cohort study

BMJ Open ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. e040253
Author(s):  
Anna Jansana ◽  
Isabel Del Cura ◽  
Alexandra Prados-Torres ◽  
Teresa Sanz Cuesta ◽  
Beatriz Poblador-Plou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Health Services ◽  
Cancer Survivors ◽  
Real World ◽  
Breast Cancer Survivors ◽  
Population Based ◽  
Real World Data ◽  
World Data

IntroductionBreast cancer has become a chronic disease due to survival improvement and the need to monitor the side effects of treatment and the disease itself. The aim of the SURBCAN study is to describe comorbidity, healthcare services use and adherence to preventive recommendations in long-term breast cancer survivors and to compare them with those in women without this diagnosis in order to improve and adapt the care response to this group of survivors.Methods and analysisPopulation-based retrospective cohort study using real-world data from cancer registries and linked electronic medical records in five Spanish regions. Long-term breast cancer survivors diagnosed between 2000 and 2006 will be identified and matched by age and administrative health area with women without this diagnosis. Sociodemographic and clinical variables including comorbidities and variables on the use of health services between 2012 and 2016 will be obtained from databases in primary and hospital care. Health services use will be assessed through the annual number of visits to primary care professionals and to specialists and through annual imaging and laboratory tests. Factors associated with healthcare utilisation and comorbidities will be analysed using multilevel logistic regression models. Recruitment started in December 2018.Ethics and disseminationThis study was approved by the Ethics Committee of Parc de Salut Mar. The results of the study will be published in a peer-reviewed journal and will be presented at national and international scientific conferences and at patient associations.Trial registration numberThis protocol is registered in Clinical Trials.gov (identifier: NCT03846999).

Practice patterns of platinum chemotherapy use in a population-based cohort of women with nonmetastatic triple-negative breast cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18590-e18590
Author(s):  
Tess King ◽  
Catherine R. Fedorenko ◽  
Li Li ◽  
Rachel Lynn Yung
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Real World ◽  
Triple Negative ◽  
Practice Patterns ◽  
Early Stage ◽  
Stage I ◽  
Complication Rates ◽  
Breast Cancer Patients ◽  
Real World Data

e18590 Background: The use of platinum agents (PT) in neoadjuvant chemotherapy (CTX) for triple negative breast cancer (TNBC) has been debated in research and practice guidelines. In high risk patients, the addition of PT to standard anthracycline and taxane regimens improves pathological complete response without definitive evidence of survival benefit (Korde JCO 2021). Due to PT’s toxicities and unclear benefit in early stage breast cancer, this study aimed to elucidate the real world practice patterns of PT use and overuse in breast cancer patients. Methods: The cohort was defined as women with stage I-III TNBC (ER, PR, and Her2 negative) who received curative intent surgery between 2011-2018. We utilized the Hutchinson Institute for Cancer Outcomes Research (HICOR) database, which links enrollment and claims records from commercial and public health insurance plans with clinical information from Washington state cancer registries (Manohar JACR 2020). We hypothesized there was overuse of PT CTX in this cohort. Overuse was defined as PT use in stage I, in the adjuvant period (NCCN 2020), and in nonstandard CTX regimens (PT use without taxane and anthracycline (NCCN 2020)). Results: Of the 910 women in the cohort, average age was 63, 90% were white, 682 (75%) received CTX, and 36% had commercial insurance, versus 53% with public insurance (Medicare 45%, Medicaid 8%). Of those receiving CTX, 39% received neoadjuvant and 67% adjuvant. Of those receiving CTX, 85 (13%) received PT, and 28 (4%) received PT without anthracycline. Of those receiving PT, 20% had stage I disease, and of those receiving adjuvant CTX, 43 (9%) received PT in the adjuvant period. Conclusions: We found there was overuse and nonstandard use of PT in this real world data. This overuse was demonstrated by the fact that 20% of women receiving PT had low risk stage I disease, and 9% of women receiving adjuvant CTX received PT in the adjuvant period. Additionally, there was nonstandard use, with 4% of women getting CTX receiving PT without anthracycline. Next steps in this research are to evaluate factors influencing overuse and nonstandard use, as well as complication rates with PT use and overuse.[Table: see text]

Real-world data regarding the efficacy of neoadjuvant carboplatin-paclitaxel followed by dose-dense adriamycin-cyclophosphamide for triple-negative early breast cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e12559-e12559
Author(s):  
Ajay Ashok Bhojwani ◽  
Helen Flint ◽  
Benjamin James Hall ◽  
Helen Wong ◽  
Helen Innes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Real World ◽  
Triple Negative ◽  
Patient Choice ◽  
Real World Data ◽  
World Data ◽  
Surgery Outcome ◽  
Post Surgery ◽  
Platinum Based Chemotherapy ◽  
Clinical Records

e12559 Background: Platinum based regimens in the neoadjuvant (NA) setting for triple negative breast cancer (TNBC) have resulted in a significant increase in the pathological response (pCR) rate but at the cost of worse hematological toxicities. Despite these data such NA regimens are not widely used as yet for TNBC. Currently, no real world evidence exist regarding the efficacy and toxicity of this treatment regimen. Methods: Patients treated with neoadjuvant carbo-pac-ddAC between December 2015 and May 2018 at Clatterbridge Cancer Centre NHS Foundation Trust were identified via pharmacy records. Clinical records were reviewed, and clinico-pathological information and toxicity data were recorded. Data lock was January 16, 2019. Results: 53 female patients were identified with a median age of 48 years (IQR: 40.0-55.5). At presentation: Median tumour size 29mm (IQR: 20.0-40.0), 45% (24/53) were LN +, 8% (4/53) were ER+. Of 30 patients tested for germ line susceptibility, 23% (7/30) were found to have a BRCA mutation (full details to be presented). Delivery of planned CT : 4% (2/53) discontinued early for progressive disease or patient choice; of the remaining patients there were a total of 36 deferrals and 8 dose reductions. Surgical details: Breast: 42% (22/53) mastectomy & 58% (31/53) WLE, Ax management: 37% (19/51) Ax clearance & 63% (32/51) sentinel node biopsy (2 patients underwent previous axillary treatment for prior BC). Of 24 patients LN+ at presentation 58% (14/24) underwent Ax clearance; of these 64% (9/14) had no Ax involvement. pCR rate (ypT0/is, N0) (cases with prior ipsilateral Ax surgery excluded) was 53% (27/51) & pCR breast alone: 60% (31/52). Radiotherapy: 90% (47/52) received radiotherapy post-surgery. Outcome: At a median follow up 42.4 wks (IQR: 34.2-54.4), 6% (3/52) patients had disease recurrence resulting in 2 deaths. Conclusions: These initial real world data confirm the efficacy of NA therapy with carbo-pac-ddAC, with pCR rates consistent with literature. These results support the use of platinum based chemotherapy in the NA management of TNBC. Updated outcomes will be presented based on pCR versus no pCR; and BRCA status.

scholarly journals Role of locoregional surgery in patients with de novo stage IV breast cancer: analysis of real-world data from China

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Li Ma ◽  
Yunzhe Mi ◽  
Shude Cui ◽  
Haibo Wang ◽  
Peifen Fu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Real World ◽  
Triple Negative ◽  
Metastatic Breast ◽  
Stage Iv ◽  
Real World Data ◽  
World Data ◽  
Surgery Group ◽  
Stage Iv Breast Cancer

Abstract Stage IV breast cancer is metastatic breast cancer (MBC). Because real-world data are lacking in China, our research attempts to explore the effect of locoregional surgery on the prognosis of patients with MBC. A total of 987 patients from 10 hospitals and 2 databases in East China (2004–2018) were included in this study. Overall, 47% of patients underwent locoregional surgery, and 53% did not. Surgeons tended to perform surgery on patients with small tumours (T1/T2), positive hormone receptor (HR) markers, and metastatic sites confined to a single organ and non-visceral sites (bone only/others) (each p < 0.05). Kaplan–Meier survival curves and the log-rank test showed that median survival was longer for patients who had locoregional surgery than for those who did not (45.00 vs. 28.00 months; p < 0.001). Patients who underwent surgery after systemic treatment had better survival than those who underwent surgery immediately (p < 0.001). In most subgroups, overall survival (OS) was significantly longer in the surgery group than in the no-surgery group (each p < 0.05), except for brain metastases and triple negative breast cancer. Therefore, we concluded that locoregional surgery for the primary tumour in MBC patients was associated with a marked reduction in risk of dying except for patients with brain metastases or triple-negative subtype.

Sign in / Sign up

Export Citation Format

Share Document